Lyell Immunopharma Reports Third-Quarter 2026 Financial Results

Lyell reported a Q3 2026 net loss of $45.5M, versus $38.8M in Q3 2025. Cash, equivalents and marketable securities were $194.0M at September 30, 2026, versus $247.2M at December 31, 2025; the company says resources, including November's $80.0M private placement proceeds, are expected to fund operat…